| Literature DB >> 33997505 |
Mei-Chen Wan1, Wen Qin1, Chen Lei1, Qi-Hong Li2, Meng Meng1, Ming Fang1, Wen Song1, Ji-Hua Chen1, Franklin Tay3, Li-Na Niu1,4.
Abstract
Marine resources have tremendous potential for developing high-value biomaterials. The last decade has seen an increasing number of biomaterials that originate from marine organisms. This field is rapidly evolving. Marine biomaterials experience several periods of discovery and development ranging from coralline bone graft to polysaccharide-based biomaterials. The latter are represented by <span class="Chemical">chitin and chitosan, marine-derived collagen, and composites of different organisms of marine origin. The diversity of marine natural products, their properties and applications are discussed thoroughly in the present review. These materials are easily available and possess excellent biocompatibility, biodegradability and potent bioactive characteristics. Important applications of marine biomaterials include medical applications, antimicrobial agents, drug delivery agents, anticoagulants, rehabilitation of diseases such as cardiovascular diseases, bone diseases and diabetes, as well as comestible, cosmetic and industrial applications.Entities:
Keywords: Biological properties; Biomedical applications; Marine biomaterials; Marine biopolymers; Marine organisms
Year: 2021 PMID: 33997505 PMCID: PMC8102716 DOI: 10.1016/j.bioactmat.2021.04.028
Source DB: PubMed Journal: Bioact Mater ISSN: 2452-199X
Fig. 1A) Structural formula of chitin and chitosan; B) Monosaccharides in glycosaminoglycans; C) Chemical structures of different forms of carrageenan; D) Putative anti-inflammatory mechanisms of fucoidan; E) Collagen extraction process for producing acid-soluble and pepsin-soluble marine collagen. Tissue homogenization is conducted with the aim of size reduction via physical methods and mild chemical pretreatment. Ethylenediamine tetra-acetic acid or HCl is then employed to demineralize the raw materials to facilitate extraction. Acidic solutions (e.g. CH3COOH) are subsequently used for dissolving the demineralized collagen to complete the extraction process. Pepsin is co-cultured with the mixture for eradication of non‐collagenous components. Finally, the soluble collagen is processed via lyophilization by mixing the collagen pellets, CH3COOH and H2O. (A is reproduced from Ref. [33] with permission from the publisher; B is reproduced from Ref. [34] with permission from the publisher; C is reproduced from Ref. [35] with permission from the publisher; D is reproduced from Ref. [36] with permission from the publisher; E is reproduced from Ref. [37] with permission from publisher).
Collagen derived from marine organisms.
| Genre | Source | Scientific Name | Collagen Type | Activity | Refs |
|---|---|---|---|---|---|
| Invertebrate organisms | Jellyfish | Collagen V/XI | Healthy food. | [ | |
| Jellyfish | Collagen I | Enhance cell migration, heal wound, hemostatic properties, modulate chondrogenic differentiation of human mesenchymal stem cells and cell culture substrate. | [ | ||
| Jellyfish | Collagen I | Trigger similar responses in cell adhesion, proliferation or migration | [ | ||
| Jellyfish | Collagen I | Support cell attachment and proliferation | [ | ||
| Sea urchin | Collagen I | Skin regenerative medicine and collagenous extracellular matrix biomaterials for tissue engineering | [ | ||
| Squid | Collagen II | Degenerative osteoarthritis-relieving effects | [ | ||
| Persian Gulf squid skin | Collagen I | Anti-cytotoxic properties | [ | ||
| Starfish | Collagen I | Production of two-dimensional membranes | [ | ||
| Vertebrate organisms | Cat Fish | Collagen I | Food, medical and cosmetic industries, produce high-value-added product | [ | |
| Cat Fish | Collagen I | Substitutes for commercial collagen | [ | ||
| Sponges | Collagen IV | ROS scavenging capability; photo-protective activivy as well as wound-healing characteristic | [ | ||
| Blue Shark | Collagen I | Promote osteoblast proliferation rates | [ | ||
| Blue Shark | Collagen II | Antioxidant activity and increase apoptotic gene expression | [ | ||
| Salmon | Collagen I | Accelerate wound healing by altering cutaneous microbiome colonization | [ | ||
| Yellowfin tuna | Collagen I | Antioxidant activities | [ | ||
| Sardine | Collagen I | Mosquito larvae against | [ | ||
| Salmon | N/A | Collagen I | Protect DNA against oxidation-induced damage | [ | |
| Medusa fish | Collagen I | Antibacterial active food and packaging film | [ |
Marine-derived enzymes.
| Name of enzymes | Sources | Enzyme type | Activity | ref |
|---|---|---|---|---|
| Asparaginase | Convert | [ | ||
| Carbonic anhydrase containg cadmium | Metalloenzymes | Catalyze the reversible hydration of CO2 | [ | |
| Alkaline protease | Protease | Peptide hydrolases | [ | |
| Extracellular phospholipase C | Lipases | Hydrolyze different oils | [ | |
| Chitinase | Hydrolase | Degrade chitin and chitosan | [ | |
| Alginate lyases | Lyases | Degrade alginate | [ | |
| Agarases | Hydrolase | Hydrolyze agar | [ | |
| Carrageenases | Hydrolase | Degrade carrageenans | [ | |
| Cellulose and hemicellulose hydrolase | Hydrolase | Break down cellulose | [ |
Fig. 2Marine enzymes and protein-based bioadhesives. A) Schematic of the reaction mechanism of l-asparaginase. B) Monomeric units of natural-derived eumelanin and polydopamine melanin (PDAM). i) dopamine (DA); and ii) DOPA, DHI; iii) DHICA; and iv) the porphyrin-like tetramer. C) Schematic of MAPs and their functional location in a byssal plaque. D) Schematic of the adhesive mechanism of catechols. As a DOPA analog, catechols are considered significant groups for wet adhesion because they possess strong bidentate binding ability toward mineral oxide surfaces. (A is reproduced from Ref. [153] with permission from the publisher; B is reproduced from Ref. [154] with permission from publisher; C is reproduced from Ref. [155] with permission from the publisher; D is reproduced from Ref. [156] with permission from the publisher).
Fig. 3Chemical structures of marine secondary metabolites. (A) The core of mycosporine-like amino acids (MAAs) is composed of a cyclohexenone, or a cyclohexenimine ring conjugated to an amino acid residue or its imino alcohol; (B) MAA precursor 4-deoxygadusol and common MAAs. The latter include mycosporine-glycine, mycosporine-2-glycine, shinorine, palythine and porphyra-334. The maximum absorbance values of these molecules are included. (A, B are reproduced from Ref. [222] with permission from the publisher).
Fig. 5(A) Images of the scleractinian coral Acropora digitifera. (B) SEM images of ultrastructural features of the coral Balanophyllia europaea. (C) Sectional view of calcium carbonate spines derived from the sea urchin Heterocentrotus mammillatus. (D) SEM images of the inner structures of sea urchin spines (A,B are reproduced from Ref. [227] with permission from the publisher; C,D are reproduced [226] from with permission from the publisher).
Fig. 4Marine skeleton with hierarchical and porous architecture applied for tissue engineering and drug delivery system, including sea urchin, cuttlebone, coral with interconnected porous structures and seashells with dense lamellar structure (reproduced from Ref. [223] with permission from the publisher).
Fig. 6(A) Optical image of a Patella pellucida shell that reflects light. (B) Optical image of reflection from a single stripe. (C,D,E) Types of microstructures observed in the shell of blue-rayed limpet. (F,G) Macroscopical and microscopical views of Tridacna maxima and T. derasa. (F) Top view of two T. maxima approximately 4–5 cm in length. (G) Transmission electron micrograph of a T. derasa iridocyte in cross section. (A,B,C,D,E are reproduced from Ref. [236] with permission from the publisher; F,G are reproduced from Ref. [238] with permission from the publisher).
Marine-derived chemotherapeutics in clinic trials.
| Stage | Compound Name | Source | Molecular Target | Interventions | Cancer Types | Status | NCT number | Refs |
|---|---|---|---|---|---|---|---|---|
| Phase III | Plitidepsin (Aplidin®) | Rac1 and JNK activation | Plitidepsin; Dexamethasone | Relapsed/refractory myeloma | Completed; Has Results | [ | ||
| Phase III | Plinabulin | Inhibit tubulin polymerization | Plinabulin; Nivolumab | Recurrent or metastatic non-small cell lung cancer in Stage IIIB-IV, | Terminated; Has Results | [ | ||
| Phase III | Depatuxizumab mafodotin ABT-414 | N/A | Noncleavable maleimidocaproyl linker, epidermal growth factor receptor and microtubule cytotoxin | ABT-414; | Glioblastoma multiforme | Completed | [ | |
| Phase III | Salinosporamide A | Suppressing the MAPK pathway | Marizomib; Temozolomide; Radiotherapy | Newly diagnosed glioblastoma | Active, not recruiting | N/A | ||
| Phase III | Lurbinectedin (Zepsyre®) | Trabectedin | Phosphorylated RNA polymerase II | Lurbinectedin; Pembrolizumab | Small cell lung carcinoma | Recruiting | [ | |
| Phase II | Polatuzumab vedotin | CD79b and microtubules | Obinutuzumab;Pinatuzumab Vedotin;Polatuzumab Vedotin;Rituximab | Relapsed or refractory B-Cell non-Hodgkin's lymphoma | Completed | [ | ||
| Phase II | Glembatumumab vedotin | Inhibit microtubule and monomethyl auristatin E | Capecitabine;CDX-011 | Recurrent osteosarcoma | Completed | [ | ||
| Phase II | Glembatumumab vedotin | Inhibit microtubule and monomethyl auristatin E | Glembatumumab vedotin; CDX-301 | Advanced melanoma | Terminated | [ | ||
| Phase II | Glembatumumab vedotin | Inhibit microtubule and monomethyl auristatin E | Glembatumumab Vedotin | Metastatic or locally-recurrent uveal melanoma | Completed | [ | ||
| Phase II | Tisotumab vedotin (HuMax®-TF-ADC) | Dolastatin 10 | Inhibit microtubules | Tisotumab Vedotin (HuMax-TF-ADC) | Bladder cancer, ovary cancer, prostate cancer, cervix cancer, endometrium cancer, lung cancer, esophagus cancer and squamous cell carcinoma of the head and neck | Completed | [ | |
| Phase II | Telisotuzumab vedotin | Dolastatin 10 | c-Met | ABBV-399 | Recurrent squamous cell lung carcinoma and stage IV squamous cell lung carcinoma AJCC V7 | Active, not recruiting | [ | |
| Phase II | Telisotuzumab vedotin | Dolastatin 10 | c-Met | Telisotuzumab vedotin | Non-small cell lung cancer | Recruiting | N/A | |
| Phase II | AGS-16C3F | Dolastatin 10 | ENPP3 and Inhibit Microtubules | AGS-16C3F | Metastatic renal cell carcinoma | Active, not recruiting | N/A | |
| Phase II | GSK2857916 | Dolastatin 10 | B-cell maturation antigen | GSK2857916 and Pembrolizumab | Multiple myeloma | Recruiting | [ | |
| Phase II | PM060184 | Microtubules | PM060184 | Advanced colorectal cancer | Unknown | [ | ||
| Phase II | Ladiratuzumab vedotin | Dolastatin 10 | LIV-1 and microtubules | ladiratuzumab vedotin | Small cell lung cancer, esophageal squamous cell carcinoma, gastroesophageal junction adenocarcinoma, squamous, non-small cell lung cancer, non-squamous head and neck squamous cell carcinoma, gastric adenocarcinoma, prostate cancer and melanoma | Recruiting | [ | |
| Phase II | Enfortumab vedotin | Dolastatin 10 | Nectin-4 and microtubules | Enfortumab vedotin, pembrolizumab, cisplatin, carboplatin, gemcitabine | Urothelial cancer | Recruiting | [ | |
| Phase III | Enfortumab vedotin | Dolastatin 10 | Nectin-4 and microtubules | Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection, Enfortumab Vedotin | Urinary bladder cancer, muscle-invasive | Recruiting | N/A | |
| Phase I | Enfortumab vedotin | Dolastatin 10 | Nectin-4 and microtubules | Enfortumab vedotin | Metastatic urothelial cancer | Completed | [ | |
| Phase I | Enfortumab vedotin | Dolastatin 10 | Nectin-4 and microtubules | ASG-22CE, AGS-22M6E | Neoplasms | Completed | N/A | |
| Phase I | ABBV-085 | Dolastatin 10 from | Direct against LRRC15 on CAFs | PF-06647020 | Advanced solid tumors, squamous cell carcinoma of the head and neck carcinoma of the breast, undifferentiated pleomorphic sarcoma | Completed | [ | |
| Phase I | PF-06647020 | Marine polyphenols from seaweeds | PTK7-targeted; | ASG-15ME | Breast cancer | Recruiting | [ | |
| Phase I | ASG-15ME | Dolastatin 10 from | Target SLITRK6 | AGS-67E | Metastatic urothelial cancer | Completed | [ | |
| Phase I | AGS-67E | Dolastatin 10 from | Target CD37 | AGS67E | Relapsed lymphoid malignancy | Completed | [ |
Fig. 7(A) Antimicrobial peptides (AMPs) kill bacteria by inducing membrane damage and/or internalization. An alternative antibacterial mechanism of AMPs is intracellular targeting. Some AMPs act on intracellular targets by inhibiting cell wall synthesis, nucleic acid binding and synthesis, protein production and enzyme activity. (B) Schematic of crosslinking reactions between 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) and hexamethylene diisocyanate (HMDI) crosslinking agents. (C) Various forms in which chitin and chitosan constructs can be fabricated. (D) Gelatin used for bone tissue repair. (A is reproduced from Ref. [298] with permission from publisher; B is reproduced from Ref. [299] with permission from publisher; C is reproduced from Ref. [300] with permission from publisher; D is reproduced from Ref. [301] with permission from publisher).
Biomaterials from marine organisms applied in tissue engineering.
| Biomaterials | Marine Sources | Tested cell types | Cell viability or improved properties | Application | Advantages(A) and disadvantage (DA) | Refs |
|---|---|---|---|---|---|---|
| Gelatin methacryloyl | Cold water fish | NIH3T3 cells | 90% | Tissue engineering and drug delivery | A: High degradation rate, appropriate melting and gelling points (~37 °C) | [ |
| Collagen | Salmon skin | Mesenchymal stem cells | Improved proliferative and differential ability of mesenchymal stem cells | Bone tissue engineering | A: Excellent mechanical properties, increased degradation rate and the compressive strength | [ |
| Shark skin ( | Osteoblast-like cell | Majority of the cells are viable | Bone tissue engineering | A: Bioactive stable composite structures, feasibility, low cost | [ | |
| Fish | T-Lymphocyte leukemia cell lines and osteoblast | Decreased (T-cells), | Bone tissue engineering | A: Biocompatibility, high stiffness, low biodegradation rate, and osteogenesis ability | [ | |
| Sea urchin | Fibroblast | Increased proliferation rate | Tissue regenerative medicine | A: Biocompatiblity, mechanically stable in wet conditions, resemblance the dermal layer in structure and function. | [ | |
| Alginate | Brown sea algae | Mesenchymal stem cells | Increased cell number | Bone tissue engineering | A: Excellent mechanical properties, suitability for cell attachment and spread | [ |
| Human osteoblasts | Improved osteoblasts proliferation | Bone tissue engineering, drug delivery | A: Suitable physical performance, bioactivity | [ | ||
| Chitin | Demosponge Ianthella basta | Mesenchymal stromal cells | High percentage of viability, improved differential ability | Tissue engineering and regeneration, such as artificial skin | A: Ability to improve adipogenic differentiation of cells, simplicity of the isolation, interconnected porosity and excellent biocompatibility | [ |
| Demosponge Aplysina aerophoba | Human mesenchymal stromal cells | Increased metabolic activity, cell numbers, and differential ability | Tissue engineering | A: Excellent cytocompatibility | [ | |
| Collagen-chitosan-fucoidan cryogels | Jellyfish (collagen), brown algae(fucoidan), giant squid(chitosan) | L929 cells | 70% | Tissue engineering | A: Mechanical stability, adequate porosity for cell proliferation | [ |
Fig. 8A) Properties of bioink in 3D bioprinting. B) The structure of polyunsaturated fatty acids and originated oils. C) Interrelations between polysaccharides of marine origin and drug delivery systems for advanced therapeutic applications. (A is reproduced from Ref. [326] with permission from the publisher; B is reproduced from Ref. [327] with permission from the publisher; C is reproduced from Ref. [328] with permission from the publisher).
Biomaterials from marine organisms applied in 3D bioprinting.
| Biomaterials | Marine Sources | Tested cell types | Cell density and viability | Advantages(A) and disadvantages (DA) | Application | 3D bioprinting method | Refs |
|---|---|---|---|---|---|---|---|
| Alginate | Brown algae | Mesenchymal stem cells | 85.0 ± 5.9% | A: Spatially varying mechanical microenvironment extrusion printing | Bone tissue engineering | Extrusion printing | [ |
| Alginate | Brown algae | Human mesenchymal stem cells | 84% ± 0.7% | A: Excellent scaffold fidelity and mechanical properties (higher alginate concentration); | Bone tissue engineering | Extrusion printing | [ |
| Silk-like protein (aneroin) | Sea anemone | Mouse pre-osteoblasts, rat myoblasts, mouse fibroblasts, and rat-derived mesenchymal stem cells | 99% | A: Accurate printability, structural integrity, and biocompatibility | Cartilage or skeletal tissue regeneration | Extrusion printing | [ |
| Gelatin | Cold water fish | NIH3T3 cells | Over 80% | A: Inexpensive, high emulsion stability | Drug delivery | Extrusion printing | [ |
| κ-carrageenan-gelatin hydrogel | Carrageen | C2C12 cells | Over 90% | A: Excellent structural stability and cell viability. | Biological binder for tissue scaffolds | Extrusion printing | [ |
| Chitosan | Crab shell | Mouse pre-osteoblast cells | Over 90% | A: Good viscoelastic properties, stable under physiological conditions, proper viscosity values. | Bone tissue engineering | Extrusion printing | [ |
| Carrageenan | Red algae | Mesenchymal stem cells | Dead cells were negligible | A: Excellent structural strength, cyto-compatible and non-toxic. | Tissue engineering and regeneration | Extrusion printing | [ |
Marine skeletons and other hard tissue applied in tissue engineering.
| Marine skeletons | Effective constituents | Porosity and pore size | Properties | Application | Refs |
|---|---|---|---|---|---|
| Shark teeth | Apatitic (hydroxyapatite and apatite-(CaF)), non-apatitic (whitlockite), and an apatitic phase (fluorapatite), | Pore size: ~50 μm and ~0.5–1 μm) | Enrichments of specific trace elements (Mg, F); | Bone tissue regeneration | [ |
| Mussels and oysters | Calcium carbonate | Particle size: 1.5 μm | Enhanced ECM mineralization and osteoblastic differentiation of MSC | Bone tissue regeneration | [ |
| Coral | Hydroxyapatite | Porosity: 70–75% | Excellent osseous tissue formation, carrier for growth factors | Tissue regeneration | [ |
| Acropora coral | Pores size: 412 ± 212 μm, porosity: 12 ± 4% | Interconnected large pores | Tissue regeneration | [ | |
| Cuttlebone | Porosity: 90.4 ± 3.5% | Interconnective porous structure; | Bone tissue regeneration | [ | |
| Cuttlebone | Biphasic Calcium Phosphate | N/A | Excellent degradability and bioactivity | Bone tissue engineering | [ |
| Marine sponge | Chitinous scaffolds | N/A | 3D chitinous scaffold for calcium carbonate deposition | Developed mineralized scaffolds | [ |
| Coral microparticles | Calcium carbonate | Porosity: 99.05% | Enhanced compressive properties; promotes more robust osteogenic differentiation of mesenchymal stromal cells, | Bone regeneration. | [ |
| Deep-sea bamboo coral | Calcareous structures alternated with smaller proteinaceous nodes of gorgonin | N/A | Excellent potential for colonization with human osteoblasts and osteoclasts | Tissue regeneration | [ |
Fig. 9A) New biomedical uses of coral skeletons. B) Purported cardioprotective mechanisms associated with fish and fish oil-derived n-3 PUFAs. C) Effect of marine-derived materials on bone metabolism via up-regulation of osteoblastogenesis and downregulation of osteoclastogenesis. Some are directly involved in osteoblastogenesis by increasing the expression of Runx2, BMP and other transcription factors. Others are dependent on the regulation of cytokine production (IL-6 and TNF). Marine-derived compounds suppress osteoclastogenesis through downregulating the expression of RANKL, NFATc1 and TRAP) (A is reproduced from Ref. [329] with permission from the publisher; B is reproduced from Ref. [330] with permission from the publisher; C is reproduced from Ref. [331] with permission from the publisher).